Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) EPS (Basic) : $-0.75 (TTM As of Sep. 2018)

View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals EPS (Basic)?

Keryx Biopharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2018 was $-0.14. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.75.

Keryx Biopharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2018 was $-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.75.

Keryx Biopharmaceuticals's EPS without NRI for the three months ended in Sep. 2018 was $-0.14. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2018 was -0.75.

During the past 3 years, the average EPS without NRI Growth Rate was -6.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -40.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Keryx Biopharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 43.30% per year. The lowest was 0.00% per year. And the median was -18.10% per year.

Keryx Biopharmaceuticals EPS (Basic) Historical Data

The historical data trend for Keryx Biopharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals EPS (Basic) Chart

Keryx Biopharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EPS (Basic)

Get a 7-Day Free Trial

-0.58

-1.23

-1.19

-1.52

-1.43

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EPS (Basic)	Get a 7-Day Free Trial															-0.20	-0.25	-0.18	-0.18	-0.14

Keryx Biopharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Keryx Biopharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2017 is calculated as

Basic EPS (A: Dec. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-163.44	-	0)	/	114.508
	=	-1.43

Keryx Biopharmaceuticals's Basic EPS for the quarter that ended in Sep. 2018 is calculated as

Basic EPS (Q: Sep. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-16.995	-	0)	/	120.433
	=	-0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.75

Keryx Biopharmaceuticals (NAS:KERX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Keryx Biopharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.keryx.com

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Executives

Scott A Holmes	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison	director, officer: Interim CEO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma	director, 10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison	director, officer: President and CEO	ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams	officer: General Counsel and Secretary	750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022